Advertisement

Topics

Latest "Biomarker discovery Driving technologies" News Stories

15:14 EDT 27th July 2016 | BioPortfolio

Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.

More Information about Biomarker discovery Driving technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.

Showing "Biomarker discovery Driving technologies" News Articles 1–25 of 11,000+

Relevant

University of Manchester and SCIEX open £18m Biomarker Discovery Centre

The Manchester, UK-based Stoller Biomarker Discovery Centre is a major step forward in precision medicine and making 'industrial' proteomics a reality


Biomarker Discovery Offers New Hope for TB Vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues ...

Biomarker drug discovery company Blueprint Bio receives $7.5mm in Series A round

Blueprint Bio Inc. (personalized medicine using biomarker drug discovery) secured $7.5mm in its Series A financing round from Forentis Partners LLC. The company will use the proceeds to further develop its intellectual property and support additional drug discoveries.


Biomarkers of Cancer

Biomarkers of Cancer Larry H. Bernstein, MD, FCAP, Curator LPBI   Biomarker Discovery Gets a Fix on Cancer GEN Feb 1, 2016 (Vol. 36, No. 3)   http://www.genengnews.com/gen-articles/biomarker-discovery-gets-a-fix-on-cancer/5674/ Just Because Cancer Is a Moving Target—Emerging Here, Eluding Treatment There—Doesn’t Mean It Can’t Be Tracked Kathy Liszewsky http://www.genengnews.com/Med...

Epistem announces collaboration with Sanofi Aventis

Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression profiling and immunohistochemistry technologies. Under the terms of the agreement sanofi-aventis has entered into a 3 year collaboration with Epistem to provide discovery through to clinical biomarke...

Stemina Biomarker Discovery Announces Rebranding of Its Diagnostics Business, New Board Member Kevin Krenitsky, MD, and Progress from Its Clinical Study

Tuesday, May 10th 2016 at 1:32pm UTC MADISON, Wis.–(BUSINESS WIRE)– Stemina Biomarker Discovery Inc. today announced it has rebranded its diagnostics business to more accurately represent its focus on neurological disorders. NeuroPointDX is transforming diagnosis and allowing more precise treatment of neurological disorders based on the patient’s metabolism. The company’s proprieta...

Biomarker drug discovery company Blueprint Bio receives $7.5mm in early-stage funding

Blueprint Bio Inc. (personalized medicine using biomarker drug discovery) secured $7.5mm in early-stage funding from Forentis Partners LLC. The company will use the proceeds to further develop its intellectual property and support additional drug discoveries.

Biomarker discovery offers hope for new TB vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.

C4X Discovery acquires more drug discovery technology from insolvent MolPlex

British company C4X Discovery has acquired a suite of advanced drug-discovery technologies from MolPlex…

Denovo Biomarkers: Robert Little. Providing a novel biomarker solution to personalize drug development

Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.

Horizons of drug discovery

Horizons of drug discovery Larry H. Bernstein, MD., FCAP, Curator LPBI   Phenotypic and Biomarker-based Drug Discovery NY Acad Sci.    http://www.nyas.org/Publications/Ebriefings/Detail.aspx Organizers: Michael Foley (Tri-Institutional Therapeutics Discovery Institute), Ralph Garippa (Memorial Sloan-Kettering Cancer Center), David Mark (F. Hoffmann-La Roche), Lorenz Mayr (Astra Zeneca), Joh...

Ten New Grants Support Alzheimer's Drug Discovery & Biomarker Development

Metabolomics in rheumatic diseases: desperately seeking biomarkers

In the setting of inflammatory diseases, metabolic profiling has potential applications in diagnosis, monitoring and defining disease pathogenesis. This Review focuses on metabolomic studies in rheumatic diseases, including discussion of state-of-the-art technologies, recent insights into disease mechanisms and treatment targets, and the feasibility of metabolomics for biomarker discovery.

Technology, not capacity, driving Catalent’s biologics strategy

Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.

Parkinson's Disease Biomarker Found in Urinary Samples

A biomarker helps physicians predict, diagnose or monitor disease, because the biomarker corresponds to the presence or risk of disease,...

BluePen Biomarkers announces collaboration with the University of Pennsylvania

(University of Pennsylvania) The University of Pennsylvania has co-founded and structured BluePen Biomarkers in collaboration with BluePrint Bio, Inc. and Emerald Logic, Inc. to conduct biomarker research and identification. BluePen is creating a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalized medicine.

Richard Buller, VP at Pfizer, to Give a Keynote at GTCbio’s Biomarker Summit Europe 2016

Berlin, Germany, July 10, 2016 --(PR.com)-- Richard E. Buller, Vice President of Oncology, Clinical Development & Head of Global Product Development at Pfizer will give a keynote presentation on, "Feedback Loops Between Biomarkers and Targeted Agents in Clinical Trials and Beyond: Lessons from Anaplastic Lymphoma Kinase (ALK+) Driven Non-Small Cell Lung Cancer (NSCLC)" at GTCbioR...

Research discovers neuroprotective protein in blood is biomarker of Alzheimer's disease

(American Friends of Tel Aviv University) A new discovery by Tel Aviv University researchers takes the medical community a leap forward in the process of effectively screening and diagnosing Alzheimer's disease. The study proposes a new biomarker for cognitive aging and Alzheimer's disease, the levels of which can be easily monitored in routine blood tests.

Glycomics and Glycoproteomics by CESI-MS for Biomarker Discovery and Biopharmaceutical Characterization

Glycosylation is one of the most prevalent co- and post-translational modifications of human proteins and is known to affect the protein properties. Glycosylation is known to be involved in many different diseases. The sialic acids at the end of the glycan chain serve as a binding site for toxins, pathogens and human lectins in a linkage-specific manner having great biomarker potential. During th...

T2 Biosystems Announces Research and Development Collaboration with Bayer to Advance Drug Monitoring and Biomarker Discovery for Blood Coagulation Disorders

LEXINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop to...

Driving, dementia: Assessing safe driving in high-risk older adults

Driving is a very complex process. Today, almost half of all drivers on the roadways are over the age of 65. With the decline of cognitive processes in older adults such as Alzheimer's disease, there is heightened concern for public safety and unsafe driving in this population. Understanding the cognitive factors that inhibit effective driving as well as recognizing older adults who may be at risk...

Quest Diagnostics spins Enterix's biomarker business off into newco Clinical Genomics

Following its acquisition of colorectal cancer testing company Enterix Inc. earlier this year, Quest Diagnostics Inc. has spun off that company's biomarker business into a new firm, Clinical Genomics Technologies Pty. Ltd. Quest holds a 19.9% equity stake in the spin-off, according to regulatory filings.

Driving, dementia -- assessing safe driving in high-risk older adults

(Florida Atlantic University) Driving is a very complex process. Today, almost half of all drivers on the roadways are over the age of 65. With the decline of cognitive processes in older adults such as Alzheimer's disease, there is heightened concern for public safety and unsafe driving in this population. Understanding the cognitive factors that inhibit effective driving as well as recognizing o...

Biomarker Market for Diagnostic Applications is Expected to Reach $30.6 Billion Globally by 2020

Portland, OR, June 19, 2016 --(PR.com)-- According to a new report titled "Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forec...

Crawford Technologies' New Voiceye Solution Featured on Discovery Channel's NewsWatch Program

Toronto, ON (PRWEB) March 17, 2016 Crawford Technologies announced today that its new Voiceye solution – allowing visually-impaired customers to read printed pages - has been featured on the Discovery’s Channel’s NewsWatch program. NewsWatch is a 30-minute segment airing weekly in more than 2...


Quick Search
Advertisement
 

News Quicklinks